Research Topics
| JENNIFER HOWITT ANOLIKSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Treatment targets in systemic lupus erythematosus: biology and clinical perspectiveValentin Marian
Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA
Arthritis Res Ther 14:S3. 2012..The innate immune system activation then feeds back, driving autoreactive B-cell and T-cell survival and maturation. This self-perpetuating disease cycle creates the opportunity for targeted treatment inventions at multiple steps...- Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factorJames J Kobie
Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
Arthritis Res Ther 13:R209. 2011..Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy... 
Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networksJennifer H Anolik
Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester, NY 14642, USA
J Immunol 180:688-92. 2008..This study provides initial evidence in humans to support the notion that anti-TNF treatment disrupts GC reactions at least in part via effects on follicular dendritic cells...- B cell biology and dysfunction in SLEJennifer H Anolik
University of Rochester School of Medicine, Rochester, NY 14642, USA
Bull NYU Hosp Jt Dis 65:182-6. 2007..Given the large body of evidence implicating abnormalities in the B cell compartment in SLE,there has been a recent therapeutic focus on developing interventions that target the B cell compartment by multiple mechanisms... - B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogenyJennifer H Anolik
Department of Medicine, Division of Clinical Immunology and Rheumatology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Clin Immunol 122:139-45. 2007..0001). Expansion of functionally immature B cells and decreased memory B cells may contribute to an immunodeficient state in patients recovering from rituximab mediated B cell depletion, particularly with repeated treatment... - New treatments for SLE: cell-depleting and anti-cytokine therapiesJennifer H Anolik
Allergy, Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Best Pract Res Clin Rheumatol 19:859-78. 2005..Moreover, many additional cytokines, such as interleukin (IL)-6, IL-18, and the type I interferons, represent interesting future targets... - Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosusJennifer H Anolik
University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
Arthritis Rheum 50:3580-90. 2004.... - B cell depletion therapy in systemic lupus erythematosusJennifer Anolik
Department of Medicine Immunology and Rheumatology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
Curr Rheumatol Rep 5:350-6. 2003..Recent open-label studies indicate that rituximab is safe and may be efficacious in the treatment of SLE, and continued study with randomized clinical trials is justified... - Down-regulation of CD20 on B cells upon CD40 activationJennifer Anolik
Department of Medicine, University of Rochester School of Medicine, Rochester 14642, USA
Eur J Immunol 33:2398-409. 2003.... - A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosusChungwen Wei
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
J Immunol 178:6624-33. 2007..These findings enhance our understanding of the B cell diversification pathways and provide mechanistic insight into the immunopathogenesis of SLE... - Treatment of SLE with anti-CD20 monoclonal antibodyR John Looney
Allergy Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Curr Dir Autoimmun 8:193-205. 2005..This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab)... 
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphomaAlison R Walker
University of Rochester, Hematology Oncology, Rochester, New York 14642, USA alison
Cancer Invest 26:431-3. 2008..The patient was started on monthly intravenous immunoglobulin treatments with complete resolution of her symptoms...- New therapies for systemic lupus erythematosus: cellular targetsR John Looney
Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14420, USA
Rheum Dis Clin North Am 32:201-15, xi. 2006..This article discusses the B-cell abnormalities found in systemic lupus erythematosus and the clinical and immunologic effects of anti-B-cell therapies... - Phenotypic and functional heterogeneity of human memory B cellsInaki Sanz
Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Semin Immunol 20:67-82. 2008.... - A perspective on B-cell-targeting therapy for SLER John Looney
Division of Allergy Immunology Rheumatology, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Room G 6427C, Rochester, NY, 14642, USA
Mod Rheumatol 20:1-10. 2010.... - B cells as therapeutic targets for rheumatic diseasesR John Looney
Department of Medicine, University of Rochester, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA
Curr Opin Rheumatol 16:180-5. 2004.... 
Reconstitution of the adult B cell repertoire after treatment with rituximabInaki Sanz
Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Arthritis Res Ther 7:175-6. 2005..The results presented by Rouzière and coworkers in their study of rheumatoid arthritis patients shed some light on this question and are discussed in this commentary...- B cells in human and murine systemic lupus erythematosusJennifer Anolik
Department of Medicine, Clinical Immunology and Rheumatology Unit, Rochester, New York 14642, USA
Curr Opin Rheumatol 16:505-12. 2004.... - Vaccine responses in patients with rheumatoid arthritisRajan Ravikumar
University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
Curr Rheumatol Rep 9:407-15. 2007..Nevertheless, it is already clear that vaccination does induce response in many patients. Unfortunately, vaccination is underutilized in RA patients and needs to be aggressively promoted... - Human innate B cells: a link between host defense and autoimmunity?Eric C B Milner
Department of Medicine, Clinical Immunology and Rheumatology Unit, University of Rochester Medical School, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
Springer Semin Immunopathol 26:433-52. 2005.... - Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndromeLahar R Mehta
Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Mult Scler 14:425-7. 2008.... - B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximabR John Looney
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Arthritis Rheum 50:2580-9. 2004..B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for SLE... - Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytesAmedeo J Cappione
Department of Medicine, Clinical Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, NY 14642, USA
J Immunol 172:4298-307. 2004..Overall, our data indicate that V(H)4.34 Abs represent a major component of the lupus IgG autoantibody repertoire and suggest that the carbohydrate moiety they recognize may act as a selecting Ag in SLE... - Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapyJennifer H Anolik
University of Rochester, Rochester, New York 14642, USA
Arthritis Rheum 56:3044-56. 2007..This study was undertaken to determine the magnitude, duration, and cause of these defects in rituximab-treated systemic lupus erythematosus (SLE) patients... - B cell depletion therapy in autoimmune diseasesInaki Sanz
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Front Biosci 12:2546-67. 2007..Finally, we will discuss some of the many challenges and opportunities that the medical and scientific community should address in the foreseeable future... - B-cell-targeted therapy for systemic lupus erythematosusRamin Sabahi
University of Rochester School of Medicine, Rochester, New York 14642, USA
Drugs 66:1933-48. 2006.... - Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosusAmedeo Cappione
Department of Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
J Clin Invest 115:3205-16. 2005..To our knowledge, this work represents the first comparative analysis of the fate of a specific autoreactive human B cell population. The results identify a defective tolerance checkpoint that appears to be specific for human SLE... - The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusJennifer H Anolik
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Arthritis Rheum 48:455-9. 2003.... - Targeted biologic approaches to the treatment of systemic vasculitisAndreea Coca
University of Rochester School of Medicine, Rochester, NY 14642, USA
Clin Rev Allergy Immunol 35:79-87. 2008..Although most of these agents remain unproven until ongoing randomized clinical trials are complete, their introduction heralds a new era of vasculitis treatment and has provided novel insights into disease pathogenesis...
Research Grants
- B-Cell Tolerance Mechanisms in Human SLEJENNIFER HOWITT ANOLIK; Fiscal Year: 2010..The knowledge gained from the present studies will help us understand the multiple functions of B cells in autoimmunity and develop better strategies for the treatment of lupus and other autoimmune diseases. ..
- B-Cell Tolerance Mechanisms in Human SLEJennifer Anolik; Fiscal Year: 2009..The knowledge gained from the present studies will help us understand the multiple functions of B cells in autoimmunity and develop better strategies for the treatment of lupus and other autoimmune diseases. ..
- B cell functional and signaling abnormalities in SLEJennifer Anolik; Fiscal Year: 2006..abstract_text> ..
- B-Cell Tolerance Mechanisms in Human SLEJennifer Anolik; Fiscal Year: 2009..The knowledge gained from the present studies will help us understand the multiple functions of B cells in autoimmunity and develop better strategies for the treatment of lupus and other autoimmune diseases. ..